-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $35

Benzinga·05/26/2026 14:28:03
Listen to the news
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $40 to $35.